Content options
A 68% remission rate means that about two in every three people in the trial no longer met the criteria for PTSD at the end of the study period, according to the headline reported by Science Daily. That is a strong result on paper. It does not yet tell you whether the treatment beats existing options, how long the benefit lasts, or whether you can get it.
We should be upfront about one thing. The source we have is a headline that describes a “breakthrough PTSD treatment” with a 68% remission rate in a clinical trial. It does not give us the trial size, the control group, or the exact treatment details, so this guide explains how to read a number like this rather than guessing at specifics.
Key takeaways
- Remission usually means symptoms fell below a diagnostic or scoring threshold. It does not mean the trauma is erased or that symptoms can never return.
- One trial, especially a small one without a comparison group, cannot prove a treatment is better than current therapy.
- Proven treatments already exist, including trauma-focused therapy and certain medicines, and you should not delay them while waiting for something new.
- If symptoms last more than a few weeks and disrupt daily life, speak to a doctor or mental health professional.
What does remission mean in a PTSD trial?
In clinical research, remission is a defined cut-off, not a feeling. Researchers typically measure PTSD symptoms with a structured clinician interview or a questionnaire, then decide in advance what score counts as “no longer meeting criteria” or “minimal symptoms”.
That matters because different trials use different yardsticks. One study may count remission when a person falls below the diagnostic threshold. Another may require a lower score, or require it to hold across two assessments. A 68% figure under a strict definition is more impressive than 68% under a loose one.
Remission is also different from response. Response usually means symptoms improved by a set amount, say a meaningful drop in score, even if the person still has PTSD. Remission is a higher bar. So it is a good sign that the headline uses the stricter word, but we still need to see how the authors defined it.
How to read “68%” with a simple example
Percentages hide the number of real people behind them. Take two imaginary trials that both report 68%.
- Trial A: 25 participants, 17 in remission. 17 ÷ 25 = 0.68, or 68%.
- Trial B: 250 participants, 170 in remission. 170 ÷ 250 = 0.68, or 68%.
The headline number is identical, but the confidence we can place in it is not. With only 25 people, a statistical estimate of the true rate could plausibly range from roughly 48% to 83%. With 250 people, the range narrows a lot. This is why the sample size is the first thing to look for.
Who is counted in the denominator?
Dropouts can change the picture. Imagine 50 people start a treatment and 40 finish. If 27 of those 40 are in remission, the report could say 27 ÷ 40 = 67.5%, which rounds to 68%. But out of everyone who started, it is 27 ÷ 50 = 54%.
Neither calculation is dishonest by itself, because researchers report both kinds of analysis. You just need to know which one the 68% refers to. Trauma treatments can be emotionally demanding, so dropout is a real issue and not a technicality.
If this kind of reading is new to you, our explainer on how a skin cancer vaccine works and what ‘half’ means walks through a similar problem: a striking percentage that needs context before it means anything.
How does 68% compare with current PTSD treatments?
Honest comparison is harder than it looks. Existing first-line care for PTSD includes trauma-focused psychotherapies and some antidepressant medicines. In trials of these, a substantial share of people improve, and a smaller share reach full remission. Published figures vary widely by study, population and definition, and are often cited somewhere between roughly 40% and 60% no longer meeting PTSD criteria after trauma-focused therapy. Treat that as a loose range, not a benchmark.
So 68% could sit at the high end of what we already see, or above it. But comparing a number from one trial against a different trial, with different patients and different measures, is not the same as testing two treatments head to head. Only a trial that compares them directly, or against a well-designed control group, can say that.
| Option | What it involves | Status |
|---|---|---|
| Prolonged exposure therapy | Gradually facing trauma memories and avoided situations with a trained therapist | Widely recommended in guidelines |
| Cognitive processing therapy | Examining and reworking unhelpful beliefs about the trauma | Widely recommended in guidelines |
| EMDR | Structured therapy involving recalling trauma while following guided eye movements or similar stimulation | Recommended in many guidelines |
| SSRIs and similar medicines | Daily medication, such as sertraline or paroxetine, prescribed by a doctor | Established, with some approved for PTSD in several countries |
| New treatment in the headline | Details not confirmed in our source notes | Trial stage per the headline; approval status unknown to us |
What are the limits of a single clinical trial?
A positive trial is a reason for interest, not a reason to switch treatments. These are the questions that decide how much weight a result can carry.
- Was there a control group? PTSD trials often show large improvement even in people given placebo or standard care, partly because attention and support themselves help. A treatment needs to beat that, not just beat no treatment.
- How big was the trial? Small groups produce shaky percentages, as the example above shows.
- Who was included? Many trials exclude people with substance use problems, suicidal thoughts or several other conditions. Real patients often have exactly those complications.
- How long was follow-up? Remission at the end of treatment is different from remission six or twelve months later. PTSD symptoms can return.
- Who ran and funded it? Industry funding does not make results wrong, but independent replication builds trust.
- Was it peer reviewed? A news summary is not the paper. The full publication contains the details that matter.
Is the new PTSD treatment approved?
From the headline alone, we cannot say it is approved, and a trial result by itself does not mean it is. Regulators such as the US FDA and India’s CDSCO generally look for consistent results from larger studies, plus safety data, before a treatment can be marketed for a condition.
The path can be bumpy even for promising therapies. In 2024, the US FDA declined to approve MDMA-assisted therapy for PTSD, asking for more evidence after earlier trial results had drawn attention. We mention it only as an example of why approval depends on the whole body of evidence. We are not suggesting the treatment in this headline is that one.
Myth vs fact: what a high remission rate does and does not mean
| Myth | Fact |
|---|---|
| 68% remission means the treatment cures two in three people. | It means two in three in that trial fell below a threshold at a given time. Durability is a separate question. |
| A “breakthrough” headline means doctors can prescribe it now. | Headlines describe research. Availability depends on regulatory approval and local access. |
| If a new treatment is promising, existing ones are outdated. | Current therapies have far more evidence behind them, and many people recover with them. |
| Remission means the person was never really traumatised. | Remission describes symptom levels. A person can recover and still carry the memory. |
PTSD symptoms and when to see a doctor
PTSD can follow an accident, violence, abuse, disaster, military service, medical emergency or sudden loss. Symptoms generally fall into four groups:
- Intrusive memories, flashbacks or nightmares about the event.
- Avoiding places, people or conversations that bring it back.
- Persistent low mood, guilt, numbness or negative beliefs about yourself or the world.
- Being constantly on edge: startling easily, irritability, poor concentration, disturbed sleep.
Many people have some of these in the first days or weeks after a shock. If they last beyond about a month, or interfere with work, relationships or sleep, it is time to see a doctor, psychiatrist or clinical psychologist. If you are having thoughts of harming yourself, contact local emergency services or a crisis line straight away.
Sleep problems are among the most common and exhausting symptoms. Good routines will not treat PTSD, but our guide to sleep hygiene habits can support recovery alongside professional care.
A note for readers in India
Trauma-trained therapists are not evenly spread across India, and many people find it hard to know where to start. A general physician or a psychiatrist at a government or private hospital is a reasonable first stop, and they can refer you onward. The government’s Tele-MANAS service offers free tele-mental-health support, with the number reported as 14416 or 1800-891-4416; please confirm the current number on the official portal before relying on it.
Under India’s Mental Healthcare Act, 2017, people have a right to access mental health care and to have their information kept confidential. Experimental treatments reported in international trials are unlikely to be available locally for a while, so asking about proven options now is the practical step. For general mental health information, the World Health Organization has plain-language resources.
What should you ask your doctor about a new PTSD treatment?
Bring this checklist to an appointment, especially if you have seen the headline and are wondering whether it applies to you.
- Which treatments with strong evidence would suit my situation and history?
- Have you seen the full trial paper, and how many people took part?
- Was the new treatment compared with an existing therapy or a placebo?
- Would someone like me, with my other health conditions or medicines, have qualified for the study?
- What side effects or risks were reported, and what is known about longer-term results?
- Is it approved or available anywhere I can reach, and is a clinical trial near me recruiting?
- Should I start standard treatment now rather than wait?
Joining a trial can be an option for some people, but it comes with screening, uncertain benefit and the chance of receiving a comparison treatment. A doctor can help you weigh that.
Common mistakes when reading health headlines
- Treating the percentage as a personal chance of recovery. Averages from a study group do not predict one person’s outcome.
- Comparing numbers from different trials as if they were a race.
- Stopping prescribed medication or therapy because something newer sounds better. Changes to medication should be made with a doctor.
- Buying unproven “PTSD protocols” online that borrow the language of research.
FAQ
What is a good remission rate for PTSD?
There is no single benchmark, because results depend on how remission is defined and who was studied. Established therapies show a wide range across trials, so a figure only means something when set against a well-matched comparison group.
Does remission mean PTSD is cured?
Not exactly. Remission means symptoms have dropped below the threshold for diagnosis. Some people stay well for years, while others have relapses, particularly during stress. Follow-up data show how lasting the benefit is.
Is the new PTSD treatment available now?
Our source describes a clinical trial result, and nothing we have confirms approval or general availability. Ask your doctor, and check with your national regulator for current status.
What are the best-proven PTSD therapy options today?
Trauma-focused psychotherapies such as prolonged exposure, cognitive processing therapy and EMDR have strong support in guidelines. Some antidepressants are also used. The right choice depends on your symptoms, preferences and access, so it needs a professional assessment.
How long should symptoms last before I seek help?
If distressing symptoms continue beyond about a month, or are severe from the start, speak to a professional. You do not need to wait for a set time if daily life is badly affected or you feel unsafe.
Bottom line
A 68% remission rate is worth watching, but a single trial headline is a starting point, not a verdict. Look for the size of the study, the comparison group, the definition of remission and the follow-up period before getting excited. If PTSD symptoms are affecting your life, do not wait for a new therapy: book an appointment with a doctor or mental health professional this week and ask about options that already have strong evidence.
